Shares in biotech company Pharming rose 29.3% on the Amsterdam bourse on Tuesday following the announcement of positive results from a European clinical study into the efficacy and safety of Rhucin, used in the treatment of acute attacks of hereditary angioedema.

The European Medicines Evaluation Agency will decide later this year if Rhucin should be available on the European market.